Chapter 4: History of Cyclodextrin Production in Hungary
This chapter tells how the cyclodextrin production was started in Hungary in seventies and eighties of the 20st century, at
Tag: HPBCD
Treatment of Niemann-Pick Disease Type C using crosslinked 2-hydroxypropyl-β-cyclodextrin
Niemann-Pick Disease Type C (NPC) is a severe neurovisceral disorder that is pathophysiologically characterized by intracellular transport abnormalities leading to
Hydroxypropyl-β-cyclodextrin causes massive damage to the developing auditory and vestibular system
2-hydroxypropyl-β-cyclodextrin (HPβCD), a cholesterol chelator used to treat Niemann-Pick C1 (NPC1) lysosomal storage disease, causes hearing loss in mammals by
Results of HPBCD-enabled MTX110 Phase I Study
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, announced encouraging headline results
Cyclodextrin-impregnated masks to prevent the transmission of coronavirus
CycloLab’s submission to InnoCentive Challenge 9934291 – New Technologies to Prevent the Transmission of Coronavirus led to a favorable evaluation.
Cyclodextrin counteracts obesity associated with various diseases including susceptibility for Covid-19
Obesity has become a worldwide health crisis and is associated with a plethora of comorbidities. Cardiovascular disease (CVD) and type
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Resveratrol analogs solubilized by HPBCD show antimicrobial and anti-inflammatory effects
Scientific Report published on the recent results of Faculty of Dentistry, National University of Singapore. [1] Resveratrol (RES) is a
Ototoxicity of cyclodextrin derivatives
There are two possible mechanisms behind the ototoxicity of 2-hydroxypropyl-β-cyclodextrin (HPBCD) treatment. One is : the possible interaction of HPBCD